The Potential Regulatory Role of RNA Methylation in Ovarian Cancer

Overview

Journal RNA Biol

Specialty Molecular Biology

Date 2023 May 17

PMID 37194218

Authors

Shijie Zhao

Mengxue Zhang

Xiaolan Zhu

Jie Xing

Jiaming Zhou

Xinming Yin

Affiliations

Soon will be listed here.

Abstract

Updates in whole genome sequencing technologies have revealed various RNA modifications in cancer, among which RNA methylation is a frequent posttranscriptional modification. RNA methylation is essential for regulating biological processes such as RNA transcription, splicing, structure, stability, and translation. Its dysfunction is strongly associated with the development of human malignancies. Research advances with respect to the regulatory role of RNA modifications in ovarian cancer include N6-methyladenosine (m6A), 5-methylcytosine (m5C), N1-methyladenosine (m1A), and N7-methylguanosine (m7G). Numerous studies have demonstrated that epigenetic modifications of RNA can influence the progression and metastasis of ovarian cancer and may provide excellent targets for cancer therapy. This review highlights advances in research on RNA methylation modifications and ovarian cancer prognosis, carcinogenesis, and resistance, which could provide a theoretical foundation for designing therapeutic strategies for ovarian cancer based on RNA methylation modifications.

Citing Articles

N7-methyladenosine-induced SLC7A7 serves as a prognostic biomarker in pan-cancer and promotes CRC progression in colorectal cancer.

Wang F, Zhang S, Chen Z, Gu X, Zhang G, Zhang H Sci Rep. 2024; 14(1):30755.

PMID: 39730571 PMC: 11680768. DOI: 10.1038/s41598-024-80885-2.

METTL3, m6A modification, and EGR1: interplay affecting myocardial I/R injury outcomes.

Huang C, Zhang X, Wu S, Chang Q, Zheng Z, Xu J Cell Biol Toxicol. 2024; 41(1):7.

PMID: 39707117 PMC: 11662061. DOI: 10.1007/s10565-024-09937-7.

The Quiet Giant: Identification, Effectors, Molecular Mechanism, Physiological and Pathological Function in mRNA 5-methylcytosine Modification.

Wang R, Ding L, Lin Y, Luo W, Xu Z, Li W Int J Biol Sci. 2024; 20(15):6241-6254.

PMID: 39664561 PMC: 11628344. DOI: 10.7150/ijbs.101337.

The role of m5C RNA modification in cancer development and therapy.

Yu L, Xu H, Xiong H, Yang C, Wu Y, Zhang Q Heliyon. 2024; 10(19):e38660.

PMID: 39444404 PMC: 11497397. DOI: 10.1016/j.heliyon.2024.e38660.

Emerging role of m6A modification in ovarian cancer: progression, drug resistance, and therapeutic prospects.

Alam S, Giri P Front Oncol. 2024; 14:1366223.

PMID: 38544837 PMC: 10966408. DOI: 10.3389/fonc.2024.1366223.

References

Wang Q, Zhang Q, Li Q, Zhang J, Zhang J . Clinicopathological and immunological characterization of RNA m A methylation regulators in ovarian cancer. Mol Genet Genomic Med. 2020; 9(1):e1547. PMC: 7963423. DOI: 10.1002/mgg3.1547. View

Lee J, Choi N, Kim S, Jin M, Shen H, Kim Y . Eltrombopag as an Allosteric Inhibitor of the METTL3-14 Complex Affecting the mA Methylation of RNA in Acute Myeloid Leukemia Cells. Pharmaceuticals (Basel). 2022; 15(4). PMC: 9032718. DOI: 10.3390/ph15040440. View

Huang H, Wang Y, Kandpal M, Zhao G, Cardenas H, Ji Y . FTO-Dependent -Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling. Cancer Res. 2020; 80(16):3200-3214. PMC: 7442742. DOI: 10.1158/0008-5472.CAN-19-4044. View

Wang Y, Chen Z . Long noncoding RNA UBA6-AS1 inhibits the malignancy of ovarian cancer cells via suppressing the decay of UBA6 mRNA. Bioengineered. 2021; 13(1):178-189. PMC: 8805991. DOI: 10.1080/21655979.2021.2011640. View

Li Y, Peng H, Jiang P, Zhang J, Zhao Y, Feng X . Downregulation of Methyltransferase-Like 14 Promotes Ovarian Cancer Cell Proliferation Through Stabilizing TROAP mRNA. Front Oncol. 2022; 12:824258. PMC: 8894193. DOI: 10.3389/fonc.2022.824258. View

Hsu P, Zhu Y, Ma H, Guo Y, Shi X, Liu Y . Ythdc2 is an N-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017; 27(9):1115-1127. PMC: 5587856. DOI: 10.1038/cr.2017.99. View

Gao W, Chen L, Lin L, Yang M, Li T, Wei H . SIAH1 reverses chemoresistance in epithelial ovarian cancer via ubiquitination of YBX-1. Oncogenesis. 2022; 11(1):13. PMC: 8913663. DOI: 10.1038/s41389-022-00387-6. View

Ni X, Chen C, Cui G, Ding W, Liu J . Crosstalk of RNA Adenosine Modification-Related Subtypes, Establishment of a Prognostic Model, and Immune Infiltration Characteristics in Ovarian Cancer. Front Immunol. 2022; 13:932876. PMC: 9274011. DOI: 10.3389/fimmu.2022.932876. View

Nombela P, Miguel-Lopez B, Blanco S . The role of mA, mC and Ψ RNA modifications in cancer: Novel therapeutic opportunities. Mol Cancer. 2021; 20(1):18. PMC: 7812662. DOI: 10.1186/s12943-020-01263-w. View

10.

Wei Y, Yao D, Li L, Lu Y, Yang X, Zhang W . [Expression of METTL14 in epithelial ovarian cancer and the effect on cell proliferation, invasion and migration of A2780 and SKOV3 cells]. Zhonghua Fu Chan Ke Za Zhi. 2022; 57(1):46-56. DOI: 10.3760/cma.j.cn112141-20210925-00553. View

11.

Muller S, Bley N, Glass M, Busch B, Rousseau V, Misiak D . IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors. Nucleic Acids Res. 2018; 46(12):6285-6303. PMC: 6158595. DOI: 10.1093/nar/gky229. View

12.

Basaki Y, Hosoi F, Oda Y, Fotovati A, Maruyama Y, Oie S . Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene. 2006; 26(19):2736-46. DOI: 10.1038/sj.onc.1210084. View

13.

Liu J, Chen C, Wang Y, Qian C, Wei J, Xing Y . Comprehensive of N1-Methyladenosine Modifications Patterns and Immunological Characteristics in Ovarian Cancer. Front Immunol. 2021; 12:746647. PMC: 8588846. DOI: 10.3389/fimmu.2021.746647. View

14.

Newman E, Morgan R, Kummar S, Beumer J, Blanchard M, Ruel C . A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol. 2015; 75(3):537-46. PMC: 4344391. DOI: 10.1007/s00280-014-2674-7. View

15.

Nie S, Zhang L, Liu J, Wan Y, Jiang Y, Yang J . ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer. J Exp Clin Cancer Res. 2021; 40(1):284. PMC: 8425158. DOI: 10.1186/s13046-021-02088-1. View

16.

Yang Y, Wei Q, Tang Y, Wang Y, Luo Q, Zhao H . Loss of hnRNPA2B1 inhibits malignant capability and promotes apoptosis via down-regulating Lin28B expression in ovarian cancer. Cancer Lett. 2020; 475:43-52. DOI: 10.1016/j.canlet.2020.01.029. View

17.

Meng L, Zhang Q, Huang X . Comprehensive Analysis of 5-Methylcytosine Profiles of Messenger RNA in Human High-Grade Serous Ovarian Cancer by MeRIP Sequencing. Cancer Manag Res. 2021; 13:6005-6018. PMC: 8349203. DOI: 10.2147/CMAR.S319312. View

18.

Issa J, Baylin S, Herman J . DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia. 1997; 11 Suppl 1:S7-11. View

19.

Zhao L, Song J, Liu Y, Song C, Yi C . Mapping the epigenetic modifications of DNA and RNA. Protein Cell. 2020; 11(11):792-808. PMC: 7647981. DOI: 10.1007/s13238-020-00733-7. View

20.

Song Y, Qu H . Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer. BMC Cancer. 2022; 22(1):633. PMC: 9178823. DOI: 10.1186/s12885-022-09591-4. View